NCT02089633View on ClinicalTrials.gov

Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

October 31, 2016

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

PACOX

Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine

Trial Locations (1)

Unknown

The University of Hong Kong, Queen Mary Hospital, Hong Kong

Sponsors
All Listed Sponsors
collaborator

The University of Hong Kong

OTHER

lead

Bio-Cancer Treatment International Limited

INDUSTRY

NCT02089633 - Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC | Biotech Hunter | Biotech Hunter